Cas:592546-71-9 4-[(3-Formyl-1H-indol-1-yl)methyl]benzoic acid manufacturer & supplier

We serve Chemical Name:4-[(3-Formyl-1H-indol-1-yl)methyl]benzoic acid CAS:592546-71-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-[(3-Formyl-1H-indol-1-yl)methyl]benzoic acid

Chemical Name:4-[(3-Formyl-1H-indol-1-yl)methyl]benzoic acid
CAS.NO:592546-71-9
Synonyms:4-[(3-Formyl-1H-indol-1-yl)methyl]benzoic acid
Molecular Formula:C17H13NO3
Molecular Weight:279.29000
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:59.30000
Exact Mass:279.09000
LogP:3.20030

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-[(3-Formyl-1H-indol-1-yl)methyl]benzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-[(3-Formyl-1H-indol-1-yl)methyl]benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-[(3-Formyl-1H-indol-1-yl)methyl]benzoic acid Use and application,4-[(3-Formyl-1H-indol-1-yl)methyl]benzoic acid technical grade,usp/ep/jp grade.


Related News: Biocatalytic processing offers many advantages over using conventional metal catalysts. The superior enantio- and regioselectivity of enzymes results in higher yields of purer product—typically comprising just a single enantiomer that has been modified on only a specific site. Benzoic acid, 2-hydroxy-4-(4-quinazolinylamino)-, hydrazide manufacturers “Alcami supported this product with supply constraints and successfully developed a capsule formulation for two dosage strengths,” she explains. “The formulations group performed studies at a micro-laboratory scale using a scientifically-based approach to identify a lead prototype. 2-Benzoylamino-5,6-dihydro-4H-thiopyran-3-carbonsaeure-ethylester suppliers After examining all the evidence, it was clear that more plausible explanations for the AML cases included the conditioning treatment the patients received to clear out bone marrow cells and the higher risk of blood cancer in people with sickle cell disease. 1,3,4-Oxadiazole, 2,5-bis[4-(2,2-diphenylethenyl)-3-methoxyphenyl]- vendor & factory.